Hinge Health, Inc. (HNGE) is projected to report Q2 2026 revenue of $201.1 million and EPS of $0.28, with shares currently trading near $74.71 compared to an average analyst price target of $92.67.
Investors are primarily focused on member enrollment growth and the continued scalability of the company’s AI-powered musculoskeletal (MSK) care platform.
The report follows a robust first quarter where revenue surged 47% year-over-year, prompting management to raise its full-year 2026 revenue guidance to a midpoint of $821 million. Market participants are also looking for updates on the recently launched Migraine Care Program as the company diversifies its digital healthcare offerings to drive long-term margin expansion.